Supernus Pharmaceuticals (SUPN) exec converts 2,500 PSUs, withholds shares for tax

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. executive Padmanabh P. Bhatt, Sr. VP of IP and CSO, reported equity compensation activity involving Performance Share Units. On August 12, 2026, he exercised 2,500 Performance Share Units, converting them into 2,500 shares of common stock.

On the same date, 1,158 common shares were disposed of at $46.57 per share, representing shares withheld by the company to satisfy tax withholding requirements related to the vesting of these Performance Share Units. After the exercise, no Performance Share Units from this award remained outstanding.

Insider Trade Summary

Net Buyer: 1,342 shares

Net Buy 3 txns

Insider Bhatt Padmanabh P.

Role Sr. VP of IP, CSO

Type	Security	Shares	Price	Value
Exercise	Performance Share Unit F3	2,500	$0.00	$0.00
Exercise	Common Stock F1	2,500	$0.00	$0.00
Tax Withholding	Common Stock F2	1,158	$46.57	$54K

Holdings After Transaction: Performance Share Unit — 0 shares (Direct); Common Stock — 18,637 shares (Direct)

Footnotes (3)

1. F1. Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
2. F2. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
3. F3. On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Key Figures

Performance Share Units exercised: 2,500 units Common shares acquired via PSU conversion: 2,500 shares Shares withheld for taxes: 1,158 shares +2 more

5 metrics

Performance Share Units exercised 2,500 units Performance Share Units converted into common stock on August 12, 2026

Common shares acquired via PSU conversion 2,500 shares Shares of common stock received from PSU exercise

Shares withheld for taxes 1,158 shares Common stock withheld to satisfy tax withholding requirements

Tax withholding share price $46.57 per share Price applied to 1,158 withheld shares for tax obligations

Remaining PSUs from this award 0 units Performance Share Units remaining after the reported exercise

Key Terms

Performance Share Units, tax withholding requirements, Employee Stock Purchase Plan

3 terms

Performance Share Units financial

"the Reporting Person was awarded Performance Share Units, a portion of which vested"

Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors.

tax withholding requirements financial

"shares of common stock withheld by the Company to satisfy tax withholding requirements"

Employee Stock Purchase Plan financial

"Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

FAQ

What did SUPN executive Padmanabh Bhatt report in this Form 4?

Padmanabh P. Bhatt reported the exercise of 2,500 Performance Share Units, which were converted into 2,500 shares of SUPN common stock, plus a related share withholding transaction for taxes on August 12, 2026.

How many SUPN shares were acquired through the PSU exercise on this Form 4?

The filing shows that 2,500 Performance Share Units were exercised and converted into 2,500 shares of SUPN common stock on August 12, 2026, reflecting equity compensation vesting for the executive.

How many SUPN shares were withheld for taxes in this Form 4?

The Form 4 reports that 1,158 shares of common stock were withheld by Supernus Pharmaceuticals at $46.57 per share to satisfy tax withholding requirements related to the vesting of the Performance Share Units.

Were any Performance Share Units left outstanding for SUPN after this transaction?

For this specific award, the entry shows 0 Performance Share Units remaining following the exercise of 2,500 units, indicating that the reported PSUs tied to this transaction were fully converted.

Is the SUPN Form 4 transaction a market sale by the executive?

The filing describes 1,158 shares as withheld by the company to cover tax withholding requirements, rather than an open-market sale, and an exercise of 2,500 Performance Share Units into common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/14/2026 - 05:12 PM Accepted by SEC EDGAR 08/14/2026 - 05:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bhatt Padmanabh P.

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr. VP of IP, CSO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2026		M		2,500	A	$0	19,795(1)	D
Common Stock	08/12/2026		F(2)		1,158	D	$46.57	18,637	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Share Unit	$0	08/12/2026		M			2,500	(3)	(3)	Common Stock	2,500	$0	0	D

Explanation of Responses:

1. Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.

2. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.

3. On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)